*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Yet another experimental drug heavily touted by Pfizer Inc. has foundered in advanced testing, raising worries about productivity ...

Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury. The company said the injury went away after the person ...

See more Winnipeg Sun on Google - save as a Preferred Source ...

Pfizer said Friday it is halting the testing of a twice-daily obesity drug, citing side effects. The company said in a press release it will now focus its future efforts for the drug, danuglipron, on ...

Pfizer and Merck are reshaping growth plans after pandemic revenue declines, with acquisitions, oncology strength, and ...

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...

Texas Attorney General Ken Paxton has sued Pfizer and its drug manufacturer for allegedly providing medicine it knew to be ineffective. In a lawsuit unsealed Monday, Paxton sued Pfizer, Inc., Tris ...

Pfizer says it will continue its COVID-19 vaccine clinical trial with the testing of third-dose booster shots. Dado Ruvic/Reuters Pfizer and BioNTech on Thursday morning announced plans to study the ...

A pill to treat obesity caused liver injury in a clinical trial Pfizer said it will stop developing the drug, called danuglipron, as a result Other alternatives to injectable obesity drugs are in ...